ストックスクリーナーアプリを入手
7.73
7.21%
0.52
アフターアワーズ：
7.73
前日終値:
$7.21
開ける：
$7.21
24時間の取引高:
100.92K
Relative Volume:
1.01
時価総額：
$235.48M
収益：
$4.01M
当期純損益:
$-30.74M
株価収益率:
-8.2234
EPS:
-0.94
ネットキャッシュフロー:
$-21.73M
1週間 パフォーマンス:
+13.84%
1か月 パフォーマンス:
+20.78%
6か月 パフォーマンス:
-4.92%
1年 パフォーマンス:
+87.62%
1日の値動き範囲:
$7.21
$7.93
1週間の範囲:
$6.25
$7.93
52週間の値動き範囲:
$3.51
$9.96
Xbiotech Inc Stock (XBIT) Company Profile
Xbiotech Inc Stock (XBIT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2019-06-14 | 開始されました | Piper Jaffray | Overweight |
| 2017-04-21 | ダウングレード | Noble Financial | Buy → Hold |
| 2016-06-28 | 繰り返されました | Noble Financial | Buy |
Xbiotech Inc (XBIT) 最新ニュース
Bank of New York Mellon Corp Buys 49,863 Shares of XBiotech Inc. (NASDAQ:XBIT) - Defense World
XBiotech (NASDAQ:XBIT) vs. Harmony Biosciences (NASDAQ:HRMY) Financial Contrast - Defense World
XBiotech (NASDAQ:XBIT) Shares Pass Above 50 Day Moving Average of $6.63 - Defense World
XBiotech (NASDAQ:XBIT) Stock Price Passes Above 50-Day Moving Average of $6.63 - MarketBeat
Objective long/short (XBIT) Report - Stock Traders Daily
XBiotech (NASDAQ:XBIT) Shares Pass Above 50-Day Moving Average of $6.47 - MarketBeat
XBiotech (NASDAQ:XBIT) Stock Crosses Above Fifty Day Moving Average of $6.47 - Defense World
Is XBiotech (NASDAQ:XBIT) Weighed On By Its Debt Load? - Simply Wall St
Hidradenitis Suppurativa Market Demand, Share, Size, Trends, Forecast To 2033 - WhaTech
Cancer Cachexia Market Forecasted to Reach $3.14 Billion by 2028 with a CAGR of 6.2% - GlobeNewswire Inc.
XBiotech Inc. (NASDAQ:XBIT) Stock Holdings Increased by Vanguard Group Inc. - Defense World
XBiotech (NASDAQ:XBIT) Stock Crosses Above Fifty Day Moving Average of $6.22 - MarketBeat
XBiotech (NASDAQ:XBIT) Shares Pass Above 50 Day Moving Average of $6.22 - Defense World
XBiotech: Q2 Earnings Snapshot - CT Insider
XBIT Stock Earnings: XBiotech Reported Results for Q2 2024 - InvestorPlace
XBiotech: Q2 Earnings Snapshot - San Antonio Express-News
XBIT Stock Earnings: XBiotech Reported Results for Q2 2024 - TradingView
XBiotech: Q2 Earnings Snapshot - The Washington Post
XBiotech: Q2 Earnings Snapshot - The Advocate
XBiotech: Q2 Earnings Snapshot - Danbury News Times
XBiotech: Q2 Earnings Snapshot - CTPost
XBiotech: Q2 Earnings Snapshot - Jacksonville Daily Progress
(XBIT) Trading Signals - Stock Traders Daily
XBiotech (NASDAQ:XBIT) Stock Crosses Above 50 Day Moving Average of $6.35 - Defense World
XBiotech Inc. (NASDAQ:XBIT) most popular amongst retail investors who own 51%, insiders hold 35% - Yahoo Finance
XBiotech (NASDAQ:XBIT) Stock Crosses Above 50-Day Moving Average of $6.35 - MarketBeat
(XBIT) Investment Analysis - Stock Traders Daily
XBiotech Inc. (NASDAQ:XBIT) Sees Significant Increase in Short Interest - MarketBeat
XBiotech Inc. (NASDAQ:XBIT) Sees Significant Increase in Short Interest - Defense World
XBiotech Inc. (NASDAQ:XBIT) Shares Acquired by Empowered Funds LLC - Defense World
XBiotech Inc. (NASDAQ:XBIT) Sees Large Decrease in Short Interest - Defense World
XBiotech Inc. (NASDAQ:XBIT) Short Interest Update - MarketBeat
Pancreatic Cancer Market to Grow Rapidly by 2034, Predicts DelveInsight | Key CompaniesFibroGen, OSE Immunotherapeutics, Panbela Therapeutics, Lokon Pharma, Helix Biopharma, Tvardi Therapeutics, BioNTech, XBiotech, Lumicell, CARsgen Ther - Yahoo Finance
Long Term Trading Analysis for (XBIT) - Stock Traders Daily
XBiotech Inc. (NASDAQ:XBIT) surges 26%; individual investors who own 51% shares profited along with insiders - Simply Wall St
XBiotech (NASDAQ:XBIT) Shares Pass Below 50-Day Moving Average of $7.29 - MarketBeat
XBiotech (NASDAQ:XBIT) Share Price Crosses Below 50 Day Moving Average of $7.29 - Defense World
XBiotech Inc (XBIT) Stock: Navigating a Year of Volatility - The InvestChronicle
Analyzing Ratios: XBiotech Inc (XBIT)'s Financial Story Unveiled – DWinneX - The Dwinnex
Vertus Energy raises €8.75M Seed for Waste-to-X biotech solutions - Tech.eu
What Kind Of Investor Owns Most Of XBiotech Inc. (NASDAQ:XBIT)? - Yahoo New Zealand News
What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday? - MSN
The Psychology of XBiotech Inc Inc. (XBIT) Price Performance: Understanding Market Sentiment - The InvestChronicle
Les résultats de XBiotech d’une étude randomisée de phase 1/2 en double aveugle suggèrent l’émergence d’un traitement révolutionnaire potentiel contre le cancer du pancréas avancé - GlobeNewswire Inc.
What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday? - Benzinga
What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday? By Benzinga - Investing.com UK
XBiotech Studies Find Potential Treatment for Advanced Pancreatic Cancer - MarketWatch
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for ... - Markets Insider
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for ... - GlobeNewswire
XBITXBiotech Inc. Latest Stock News & Market Updates - StockTitan
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer - Yahoo Finance
Xbiotech Inc (XBIT) 財務データ
収益
当期純利益
現金流量
EPS
0.05%
4.86%
大文字化:
|
ボリューム (24 時間):